Radiopharm Theranostics Ltd SEC Filings

RADX NASDAQ

Welcome to our dedicated page for Radiopharm Theranostics SEC filings (Ticker: RADX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Decoding Radiopharm Theranostics’ radiopharmaceutical pipeline isn’t easy—its 20-F spans hundreds of pages on trial design, radionuclide safety data, and cash-burn projections. Finding when the HEAT HER2 study reaches a dosing milestone or spotting fresh capital-raise risks can take hours. That’s why professionals searching for “Radiopharm Theranostics SEC filings explained simply” end up here.

Stock Titan’s AI reads every 10-K-equivalent, 10-Q, 8-K and S-1 the moment EDGAR releases them, then serves plain-English summaries, key-metric dashboards, and instant alerts. Instead of wading through technical appendices, you’ll see R&D spend trends, partnership revenue splits, and Radiopharm Theranostics insider trading Form 4 transactions within seconds. Our engine cross-links trial disclosures to risk factors, so understanding Radiopharm Theranostics SEC documents with AI becomes straightforward.

Radiopharm Theranostics quarterly earnings report 10-Q filing
Radiopharm Theranostics Form 4 insider transactions real-time
Radiopharm Theranostics earnings report filing analysis
Radiopharm Theranostics executive stock transactions Form 4
Radiopharm Theranostics annual report 10-K simplified
Radiopharm Theranostics proxy statement executive compensation
Radiopharm Theranostics 8-K material events explained

Use these insights to monitor when insiders accumulate shares before pivotal data, verify cash runway ahead of Phase 2 expenses, or review how new collaborations shift revenue potential. Whether you’re a biotech portfolio manager or a sell-side analyst, Stock Titan turns raw filings into actionable intelligence, so you can focus on what really moves Radiopharm’s valuation.

06/23/2025 09:53 PM

Filing

[6-K] Radiopharm Theranostics Limited American Current Report (Foreign Issuer)

Rhea-AI Summary

Radiopharm Theranostics has filed a Form 6-K to report the signing of a significant supply agreement with Cyclotek for 161Tb-KLK3-mAb, as announced on the Australian Securities Exchange on June 24, 2025.

The filing consists of an announcement made to the Australian Securities Exchange regarding the supply agreement, which has been attached as Exhibit 99.1 to the Form 6-K. The company files annual reports under Form 20-F and is not subject to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

This Form 6-K and its exhibits are not considered "filed" for Securities Exchange Act purposes and will not be automatically incorporated by reference into future securities filings unless specifically referenced. The document was signed by Company Secretary Phillip Hains.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Radiopharm Theranostics (RADX)?

The current stock price of Radiopharm Theranostics (RADX) is $4.64 as of June 30, 2025.

What is the market cap of Radiopharm Theranostics (RADX)?

The market cap of Radiopharm Theranostics (RADX) is approximately 34.2M.

What is Radiopharm Theranostics Ltd?

Radiopharm Theranostics Ltd is an Australian clinical-stage radiotherapeutics company focused on developing innovative oncology radiopharmaceuticals for both diagnostic and therapeutic applications.

What types of technologies does the company develop?

The company develops a range of platform technologies including peptides, small molecules, and monoclonal antibodies, which are used in both imaging and targeted therapy for cancer.

How does Radiopharm generate its revenue?

As a clinical-stage company, revenue generation is centered around strategic partnerships, milestone payments, and potential future commercialization of its pioneering radiopharmaceutical products.

What are the primary areas of focus for their clinical trials?

Radiopharm conducts trials in various solid tumor cancers, including brain, lung, breast, and pancreas cancers, with specific trials targeting HER2-positive cancers and brain metastases via innovative imaging techniques.

What is the significance of their dual listing on the ASX and Nasdaq?

The dual listing enhances the company’s visibility and credibility among international investors, providing greater access to global capital and recognition of its research and development efforts.

How does Radiopharm differentiate itself from competitors?

Radiopharm differentiates itself through its integrated approach to developing both diagnostic and therapeutic radiopharmaceuticals, its strong clinical trial pipeline, and its strategic global partnerships that advance its technological expertise.

What role do strategic partnerships play in the company's operations?

Strategic partnerships are essential for Radiopharm, as they help share clinical development costs, accelerate trial progress, and expand the company’s access to advanced research and market opportunities.

Why are radiopharmaceuticals important in oncology?

Radiopharmaceuticals are pivotal in oncology because they enable targeted imaging and therapy, which can improve the accuracy of cancer detection and provide more effective, localized treatment options.